All Tumor Types
Conditions
Keywords
rare cancer, biomarker, molecular screening, cancer, biobanking
Brief summary
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Detailed description
Patients are recruited in the platform for the research purpose of 5 downstream projects. For more information, please have a look at the "Groups and cohorts" section.
Interventions
GENETICRP-1828 IMMUcan
WES, lcWGS and RNAseq, multiplex IF and IMC
GENETICRP-1759 AYA/TYA
WES, RNAseq and EPIC array
GENETICRP-1843 Arcagen
NGS panel
GENETICRP-1920 BioRadon
NGS panel
GENETIC2148 MRD
ctDNA detection and WES
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with pathologically confirmed selected tumor types (at site or centrally); * Mandatory availability of adequate human biological material (HBM); * Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; * Age ≥ 12 years; * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; * Written informed consent according to applicable legal and ethical requirements;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To establish a quality assured platform to improve the understanding of tumor biology and cancer patients care | 5 years | material (including imaging data) as well as patient-reported outcomes from patients with cancer diagnosis to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care. |
Secondary
| Measure | Time frame |
|---|---|
| To perform biospecimen and data based high quality research aiming to better understand the biology of cancer, and/or how it is currently managed and/or how to better diagnose and treat it in the future; | 5 years |
| To investigate the molecular pathways related to the development of specific tumors from a biological point of view; | 5 years |
| To investigate the effect of cancer treatment on the tumor, microenvironment and patients globally; | 5 years |
| To collect large series of homogeneous clinical data to analyse the disease course and treatment performed; | 5 years |
| To investigate the prevalence and validate the prognostic or predictive value of novel biomarkers in cancers; | 5 years |
| To perform biospecimen and data based high quality research aiming to facilitate the discovery of new test for tumor biomarkers or facilitate the establishment of validated tests for tumor biomarkers; | 5 years |
| To identify patients with molecular alterations in their tumor that can be matched to biomarker-driven clinical trials, to facilitate enrollment of cancer patients in biomarker-driven clinical trials. | 5 years |
Countries
Austria, Belgium, Croatia, Cyprus, Czechia, Estonia, France, Germany, Greece, Italy, Lithuania, Netherlands, Poland, Portugal, Romania, Serbia, Slovenia, Spain, Switzerland, United Kingdom
Contacts
CONTACTEORTC HQ
STUDY_CHAIRBenjamin Besse, Pr.
European Organisation for Research and Treatment of Cancer - EORTC
Outcome results
None listed